Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-15

Study Completion Date

2023-01-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the safety of certolizumab when it is given with the chemotherapy drugs cisplatin and pemetrexed. Cisplatin and pemetrexed are two chemotherapy drugs used in the treatment of lung cancer. The investigators want to find out what effects, good and/or bad, certolizumab has on the patient and lung cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

NCT04991025

Lung Cancer Lung Cancer Stage II Lung Cancer Stage III

RECRUITING PHASE2

S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00003587

Lung Cancer

COMPLETED PHASE2

Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00301808

Lung Cancer

COMPLETED PHASE2

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

NCT03158129

Stage I Lung Non-Small Cell Cancer AJCC v7 Stage IA Lung Non-Small Cell Carcinoma AJCC v7 Stage IB Lung Non-Small Cell Carcinoma AJCC v7 +4 more

COMPLETED PHASE2

Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00003037

Lung Cancer

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stage IV Lung Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

certolizumab, cisplatin and pemetrexed

Patients will receive certolizumab with 6 cycles of cisplatin \& pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, \& subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg \& 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.

Group Type EXPERIMENTAL

Certolizumab

Intervention Type DRUG

cisplatin

Intervention Type DRUG

pemetrexed

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Certolizumab

Intervention Type DRUG

cisplatin

Intervention Type DRUG

pemetrexed

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previously untreated stage IV lung adenocarcinoma confirmed at MSKCC
* Age 18 years or older
* Karnofsky Performance Status ≥ 70
* Patients with locally treated, stable, and/or asymptomatic brain metastases are eligible.
* Adequate bone marrow, liver and renal function, as specified below:
* Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
* Hemoglobin ≥ 8 g/dL
* Platelets ≥ 100 x 109/L
* Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with documented Gilbert's Syndrome)
* AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present
* Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal.
* Negative PPD test
* For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment
* Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter
* Presence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors
* Archival tissue (10 Unstained Slides - 5 micron sections) from a core biopsy performed and received within 30 days before signing consent or ability to have a fresh core biopsy performed
* Biopsy cannot be from any cytology or bone specimen
* Biopsy site must be amenable to re-biopsy at the end of the study
* Ability to provide written, informed consent

Exclusion Criteria

* Hypersensitivity to platinum agents
* Ongoing use of investigational agents or use of investigational agents within the last four weeks
* Prior use of agents for TNF-alpha blockade
* History of rheumatoid arthritis, inflammatory bowel disease, or psoriatic arthritis
* Baseline hearing deficit (CTCAE version 4.0 grade 2 or higher)
* Ongoing bacterial, viral, or antifungal infection requiring antimicrobial treatment with the exception of thrush
* Active tuberculosis or untreated, latent tuberculosis

o If a patient has signs, symptoms, or a history suggestive of active tuberculosis, evaluation by an infectious disease physician will be required and active tuberculosis ruled-out prior to enrollment.
* Acute or chronic Hepatitis B or C infection
* Known HIV infection requiring antiretroviral medications and those with AIDS
* Active herpes zoster infection
* Non-healed infected skin ulcers
* History of myocardial infarction or unstable angina within the past 12 months
* Ongoing use of other immunosuppressive medications, including oral steroids and excluding topical steroids
* Women who are breastfeeding Prior history of other malignancy with the exclusion of localized prostate cancer, non-melanomatous skin cancer, ductal carcinoma or lobular carcinoma in situ of the breast

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No